OsteoActivator for Osteoarthritis
Treatment of Impaired Bone Remodeling in Osteoarthritis
Key Facts
About Osteo-Pharma
Osteo-Pharma is a private, preclinical-stage biotech company pioneering a localized drug delivery platform for bone regeneration. Its core OsteoActivator™ technology encapsulates approved low molecular weight compounds in a biodegradable carrier for sustained release over 6-8 weeks, aiming to shift the bone remodeling balance towards net growth. The lead program, OsteoActivator-P for alveolar ridge preservation, has entered a clinical study in the Netherlands, while other applications in fracture healing, osteoarthritis, and implant coatings are in preclinical development. The company leverages deep bone biology expertise from its founder and a scientific advisory board to address significant unmet needs in orthopedics and dentistry.
View full company profile